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Background: The loss of RGCs expressing Thy-1 after optic nerve injury has an initial phase of rapid decline
followed by a longer phase with slower reduction rate. This study used longitudinal retinal imaging of mice
expressing cyan fluorescent protein under control of the Thy-1 promoter (Thy1-CFP mice) to determine how the
α2-adrenergic agonist brimonidine influences loss of Thy1 promoter activation.
Methods: Baseline images of the fluorescent retinal neurons in 30 Thy1-CFP mice were obtained using a modified
confocal scanning laser ophthalmoscope. Next, brimonidine (100 ug/kg, IP) was administered either one time
immediately after optic nerve crush, or immediately after optic nerve crush and then every 2 days for four weeks. A
control group received a single saline injection immediately after optic nerve crush. All animals were imaged
weekly for four weeks after optic nerve crush. Loss of fluorescent retinal neurons within specific retinal areas was
determined by counting.
Results: At one week after optic nerve crush, the proportion of fluorescent retinal neurons retaining fluorescence
was 44±7% of baseline in control mice, 51±6% after one brimonidine treatment, and 55±6% after brimonidine
treatment every other day (P<0.05 for both brimonidine treatment groups compared to the control group).
Subsequently, the number of fluorescent retinal neurons in the group that received one treatment differed
insignificantly from the control group. In contrast, the number of fluorescent retinal neurons in the group that
received repeated brimonidine treatments was greater than the control group by 28% at two weeks after crush
and by 32% at three weeks after crush (P<0.05 at both time points). Rate analysis showed that brimonidine slowed
the initial rate of fluorescent cell decline in the animals that received multiple treatments (P<0.05). Differences in
the rate of loss among the treatment groups were insignificant after the second week.
Conclusion: Repeated brimonidine treatments protect against loss of fluorescence within fluorescent retinal
neurons of Thy1-CFP mice after optic nerve crush. As most of fluorescent retinal neurons in this system are RGCs,
these findings indicate that repeated brimonidine treatments may protect RGC health following optic nerve crush.
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Loss of retinal ganglion cells (RGCs) is a well-known
consequence of optic nerve damage that occurs in a
number of diseases including glaucoma, ischemic optic
neuropathy and compressive optic neuropathy [1-3]. A
goal for neuroprotective treatment of these diseases is to
protect RGCs from damage following optic nerve injury.
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reproduction in any medium, provided the orwidely used ocular hypotensive agent, has been reported to
protect against RGC death in rodent models of optic nerve
crush, acute retinal ischemia and glaucoma [4-8]. However,
whether brimonidine can also protect RGCs from early de-
generative events remains poorly understood.
Thy-1 is a cell surface glycoprotein that in retina is
expressed on the cell bodies of healthy adult RGCs
[9,10]. During development, Thy-1 mRNA and protein
expression in RGCs increases to adult expression at two
weeks after birth in coincidence with synapse formation
at RGC innervation targets within the brain [11,12].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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within the first day after optic nerve crush that is followed
a few days later by decline in Thy-1 protein, and one to
two weeks later by RGC death [13]. Thus, the transcrip-
tion of Thy-1 mRNA and expression of Thy-1 protein by
adult RGCs are early-responding markers of adult RGC
health. Moreover, interventions that diminish or delay loss
of Thy-1 promoter activation after optic nerve crush may
reflect protection of RGC health.
Longitudinal assessment of Thy-1 promoter activation
in the retina has become more practical with the recent
development of a method to noninvasively image fluor-
escent retinal neurons in transgenic mice expressing
cyan fluorescent protein (CFP) under the control of the
Thy-1 promoter (Thy1-CFP mice) [14]. These images
show bright spots corresponding to individual fluores-
cent neurons as well as fluorescent retinal nerve fiber
layer axon bundles converging at the optic nerve head.
Following optic nerve crush, a major portion of these
fluorescent retinal neurons cease expression of CFP over
the first one to two weeks with more gradual loss occur-
ring over the subsequent two to three weeks [14]. An
important advantage of this approach for longitudinal
evaluation of the same retinal neurons is that it avoids
the uncertainty associated with having to compensate
for the normal large variation in RGC numbers among
individual mice by using large experimental group sizes
for each time point.
The present study has used this longitudinal in vivo
imaging approach to determine whether single or
multiple brimonidine treatments diminish or delay the
time-dependent loss of fluorescent retinal neurons in
Thy1-CFP mice following optic nerve crush. The optic
nerve crush model was used because the simultaneous
injury to all optic nerve axons facilitates detection of




This study used hemizygous B6.Cg-Tg (Thy1-CFP)23Jrs
mice (both male and female) approximately 3 months
old. These animals were bred at UCSD from the same
stocks that provided animals for prior studies [14,15].
All experimental procedures conformed to the ARVO
Statement for the Use of Animals in Ophthalmic and
Vision Research and were approved by the UCSD
Institutional Animal Use and Care Committee. The
animals were housed using standard vivarium enclo-
sures, provided standard food and water ad libitum, and
maintained with 12 hours light and 12 hours dark daily
light cycle. Animal health was checked daily by trained
personnel under the supervision of a laboratory research
veterinarian.Treatments
Three groups of Thy1-CFP23Jrs mice were studied fol-
lowing optic nerve crush. In the first group, brimonidine
(100 μg/kg) was administered by intraperitoneal injec-
tion only immediately after optic nerve crush. In second
group, brimonidine (100 μg/kg) was administered imme-
diately after optic nerve crush and then every 2 days for
the remainder of the study (QOD). The control group
mice received one saline injection immediately after
optic nerve crush.
BCSLO imaging
Imaging by bCSLO was performed as previously de-
scribed [14,15]. Animals were gently restrained by hand
and no anesthesia was used. A single scan corresponding
to a retinal area of about 2 mm2 was obtained in less
than 5 seconds. The short exposure period needed for
focusing and image collection was generally well toler-
ated by the mice. Both eyes were imaged at each imaging
session. This allowed monitoring of any fluorescent cell
loss for reasons unrelated to the optic nerve crush.
Experimental design
Ocular biomicroscopic examination was performed to
exclude any animals with abnormal ocular appearance.
Power analysis indicated 80% power to detect a 30% dif-
ference in the presence of a standard deviation of 8%
with P < 0.05 would be achieved if the sample size was 5
mice/group or greater. A prior study using this experi-
mental system indicated there would likely be some
losses due to technical issues [14]. Hence, 30 animals
with normal ocular appearance were randomly assigned
from each of the litters contributing to this population
to each of the three treatment groups until there were
10 animals/group. Average body weight for all animals
was 19.6 ± 2.9 grams and the means for each of the
groups differed from this value by less than 3%. Follow-
ing retinal imaging by bCSLO, monocular intraorbital
optic nerve crush was performed as previously described
[15]. Care was taken to perform the crush sufficiently
distal to the globe so that retinal circulation was pre-
served. The retinas of the eyes that received optic nerve
crush were imaged by bCSLO at 1, 2, 3 and 4 weeks
after crush. Body weight of each included animal was
measured at the time of baseline image collection and
then measured weekly for the remainder of the study as
a measure of animal health. After initiation of the study,
1 animal in the control group, 4 animals in the single
treatment group, and 3 animals in the repeated treat-
ment group were excluded due to the development of
cataract or corneal opacity during the course of the
study. Thus, there remained 9 animals in the control
group, 6 animals in the single treatment group, and 7
animals in the repeated treatment group.
Figure 1 Absence of body weight change during the course of
the study or difference among the treatment groups (P > 0.93
for each time point, ANOVA).
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All of the images for each eye that received optic nerve
crush were reviewed at the end of the experiment to
identify retinal regions in which there was good quality
imaging of the fluorescent cells from each of the exam-
ination sessions. Selected region images meeting this cri-
terion and containing at least 120 fluorescent cells at
baseline were identified for each eye based on retinal
features including blood vessels, fluorescent axon bun-
dles, and the few cells that retained their fluorescence
throughout the study. Using Photoshop (CS4, Adobe,
San Jose, CA), these defined areas were cut from each
image and the images were inverted to facilitate
counting. Masked counts of fluorescent cells in these de-
fined retinal areas were made by a counter unaware of
the experimental condition or time point of the images.
After unmasking, the counts at each time point for each
eye were expressed as percent of the baseline count in
that same eye.
Statistical evaluation
The data are expressed as mean ± standard deviations
(SD). Body weight was compared at each time point
using the Students t test. The fluorescent retinal neuron
counts at each time point in the group that received a
single briminidine treatment and in the group that re-
ceived repeated brimonidine treatments were compared
against the corresponding counts in the vehicle control
group by one-way analysis of variance (ANOVA) and
the Student-Newman-Keuls test (SNK, Primer of Bio-




The body weight of animals receiving either vehicle treat-
ment (n = 9), single brimonidine treatment (n = 6), or re-
peated brimonidine treatment (n = 7) did not change
significantly during the course of the study (P = 0.93 to
0.97 for each time point, t test, Figure 1).
Images
The bCSLO images contained bright fluorescent spots
corresponding to individual fluorescent retinal neurons
and were inverted to facilitate counting (Figure 2). Each
fluorescent retinal neuron appeared in the inverted im-
ages as dark spots while nerve fiber layer axon bundles
appeared as dark lines radiating from the optic nerve
head. Retinal blood vessels blocked background fluores-
cence (that likely originated from fluorescent RGC den-
drites in the inner plexiform layer [14]) and hence
appeared as bright branching lines in the inverted im-
ages. The structural features of the axon bundles and
blood vessels allowed the reproducible identification ofretinal areas that contained at least 120 fluorescent ret-
inal neurons in the baseline images and that were in
focus in the images from subsequent time points for
each eye.
Counts
Fluorescent retinal neuron counts in the defined retinal
areas in the vehicle control eyes at 1, 2, 3, and 4 weeks
after optic nerve crush were 44 ± 7%, 31 ± 7%, 24 ± 7%,
and 22 ± 5% of baseline counts (n = 9, black bars,
Figure 3). In the mice that received a single brimonidine
treatment, fluorescent retinal neuron counts at the same
time points were 51 ± 6%, 34 ± 4%, 27 ± 4%, and 24 ± 3%
of baseline counts (n = 6, dark gray bars, Figure 3).
These counts were 18% greater than the vehicle control
eye counts at week 1 (P < 0.05, SNK test at each time
point) but were not significantly different at weeks 2, 3,
and 4 following optic nerve crush. In the mice that re-
ceived repeated brimonidine treatments, fluorescent ret-
inal neuron counts at the same time points were 55 ± 6%,
44 ± 7%, 32 ± 7%, and 28 ± 6% of baseline counts (n = 7,
light gray bars, Figure 3). These counts were 27%, 28%, and
32% greater than the vehicle control counts at week 1,
week 2, and week 3 following optic nerve crush (P < 0.05
at each time point, SNK test).
Rate analysis
Longitudinal evaluation of changes in the rate of fluores-
cent retinal neuron loss in the vehicle treated mice de-
clined from 57 ± 7 percent of baseline counts per week
in the first week, to 13 ± 8 percent per week in the
Figure 2 Inverted fluorescent retinal neurons imaged in vivo using bCSLO at baseline (A and C) and in the same eyes at 4 weeks
(B and D) after optic nerve crush from a mouse that received saline treatment (A, B) and a mouse that received repeated brimonidine
treatment (C,D). Fluorescent neurons appear as black spots, axon bundles appear as dark thin lines radiating from the optic nerve head
(seen more easily in B and D), while retinal blood vessels appear as bright thick lines branching from the optic nerve head.
Figure 3 Preservation of fluorescent retinal neurons in defined
retinal areas of mice following optic nerve crush with a single
brimonidine treatment or with brimonidine treatment every
other day (QOD). Asterisks indicate P < 0.05 compared with the
control group.
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and 1 ± 5 percent per week in the fourth week (Figure 4).
This result is consistent with prior reports showing
faster loss during the first one to two weeks and much
slower loss rates during later weeks [15,16]. Repeated
brimondine treatment slowed the rate of loss during the
first week from 57 ± 7%/week to 45 ± 6%/week (P < 0.05,
SNK test). During the second, third, and fourth weeks,
the rate of fluorescent retinal neuron loss did not signifi-
cantly differ among the treatment groups.
Discussion
These results show that brimonidine treatment protects
against the loss of Thy-1 promoter activation that occurs
following optic nerve crush. A single treatment provided
significant protection at one week after crush, but this ef-
fect became insignificant at later time points. Repeated
brimonidine treatment, however, provided protection that
was both larger and longer lasting. Specifically, the ~30%
protection observed at one week was maintained for the
next two weeks. Rate analysis confirmed that brimonidine
significant slowed the rate of loss of cells with Thy-1 pro-
moter activation during the first week after crush and
Figure 4 Rate analysis expressed as percent of baseline
fluorescent retinal neuron loss per week. Brimonidine QOD
induced significantly slower fluorescent retinal neuron loss than
either vehicle or a single brimonidine treatment (asterisk indicates
P < 0.05).
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2 and 3 weeks after crush.
Immunohistochemical studies indicate that 20% of
CFP-expressing cells in healthy Thy1-CFP23Jrs mice are
cholinergic amacrine cells [17]. These cholinergic ama-
crine cells appear to be refractory to cell loss in a Thy1-
CFP DBA/2J mouse line in which there is spontaneous
loss of RGCs [18]. Hence, it seems reasonable to esti-
mate the loss RGCs expressing CFP in the current study
by subtracting 20% of the baseline counts from the
current observations. Performing this calculation pro-
jects that RGCs expressing CFP in the vehicle treated
mice were 24%, 11%, 4%, and 2% of baseline at 1, 2, 3,
and 4 weeks after crush. This result is consistent with
prior studies of Thy-1 expression after optic nerve crush
[13,16]. Applying this 20% adjustment to the results for
the repeated brimonidine treatment group projects that
RGCs expressing CFP were 35%, 21%, 12%, and 8% of
baseline at 1, 2, 3, and 4 weeks after crush. Thus, the
present results indicate that systemic brimonidine treat-
ment can provide substantial protection against loss of
Thy-1 promoter activation following optic nerve crush.
In agreement with an earlier study [15], the rate of loss
of fluorescent neurons following optic nerve crush was
biphasic with more rapid loss initially followed by a
period of slower loss. These two rates may reflect pro-
gression in the degenerative process or differences in the
rates of primary and secondary degeneration [3,19]. The
present observation that brimonidine significantly de-
layed the earlier more rapid phase but did not signifi-
cantly change the rate of loss in the later slower phase
suggests that its protective effect may be more importantduring the earlier phase. Nevertheless, the increased pres-
ervation of CFP-expressing RGCs obtained in the first
week was largely maintained over the next two weeks in
the animals that received continued brimonidine treat-
ments. Thus, these results indicate that brimonidine treat-
ment may protect RGC health both during the first few
days after crush as well as during subsequent weeks.
The mechanism underlying the neuroprotective effect of
brimonidine remains unclear. Prior studies suggest direct
action of brimonidine in the protection of injured neurons
since protection against RGC death can be blocked by α2-
antagonists [5,6]. The lack of a general metabolic effect is
supported by the stability of body weight during the
course of the present study. Brimonidine can increase the
expression of growth factors such as brain-derived neu-
rotrophic factor and fibroblast growth factor [20-22].
Brimonidine may also presynaptically inhibit glutamate re-
lease [7,23], as well as modulate postsynaptic NMDA re-
ceptor function [24]. In view of the protection of both early
and later degeneration phases delineated in the present
study, it will be of interest to determine how quickly these
physiological responses are altered after the initiation or
cessation of brimonidine treatment.
Several limitations of the models employed should be
considered when interpreting the present results. First,
the optic nerve crush model simultaneously triggers
RGC death that occurs within several weeks. This differs
from the typical prolonged and asynchronous course of
primary open angle glaucoma (POAG) where less than
0.02% of RGCs may be undergoing apoptosis at any one
time [3,25]. Another consideration is that loss of CFP
expression in the Thy1-CFP mouse model employed in
the present study may differ from the loss of RGC func-
tion [26]. Finally, the present experimental system does
not address possible changes in the rate of brain alter-
ations that may occur following either optic nerve crush
or glaucoma [27-29]. Nevertheless, because Thy-1 deple-
tion following optic nerve crush significantly precedes
the onset of RGC death, the present results suggest that
systemic brimonidine treatment may delay the loss of
RGC health immediately following optic nerve crush.
Conclusions
This study has demonstrated that repeated brimonidine
treatments protect against loss of fluorescence among
fluorescent retinal neurons in Thy1-CFP mice after optic
nerve crush. As most of fluorescent retinal neurons in
this system are RGCs, these findings indicate that re-
peated brimonidine treatments may protect RGC health
following optic nerve crush. Moreover, this effect is
greatest during the first week following optic nerve
crush and persists during subsequent weeks. These re-
sults support further studies to investigate whether
brimonidine can be exploited to protect RGC health
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RGC recovery in clinical conditions such as compressive
optic neuropathy or glaucoma.
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